Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Regulatory News (GNS)

Share Price Information for Genus (GNS)

Share Price is delayed by 15 minutes
Get Live Data
2,158.00    26.00 (1.22%)
Bid:
2,156.00
Ask:
2,166.00
Spread: 10.00 (0.464%)
Market Cap: £1.43b
GNS Live PriceLast checked at - London Stock Exchange

Intraday Genus Share Chart

Senior Management Changes

4 Jan 2012 07:00

RNS Number : 9387U
Genus PLC
04 January 2012
Β 

ο»Ώ

Β 

For immediate release 4 January 2012

Β 

Β 

Β 

Β 

Β 

Β 

Β 

GENUS plc

("Genus" or "the Company")

Β 

Senior Management Changes

Β 

Genus, a leading global animal genetics company, announces two senior management changes within the Group.

Β 

Firstly, Genus is delighted to announce that Catherine Glickman will join the Company as Group Human Resources (HR) Director on January 5th 2012. Catherine will be leading the Group's talent management strategy as well as taking responsibility for engaging, equipping and investing in Genus employees to help the Group deliver its ambitious plans for growth. Catherine will become a member of the Genus Executive Leadership Team and will report directly to Karim Bitar, Chief Executive Officer.

Β 

Until recently, Catherine was the Head of HR at Tesco, one of the five largest global retailers with over 500,000 employees in 14 countries. During her 20 years at Tesco she was instrumental in developing the HR strategy that helped drive the retailer's strong growth and international expansion in recent years. Overall, she has over 25 years' experience in HR, within Tesco and beyond.

Β 

Secondly, Denny Funk Ph.D, the Company's Chief Scientific Officer, has also joined the Genus Executive Leadership Team. Dr. Funk will report directly to Karim Bitar, Chief Executive, and will have full responsibility for the Company's research & development (R&D) programme. This will ensure that R&D has a key and highly visible role as Genus pursues its ambitious plans for the future. Dr. Denny Funk was an Associate Professor at the University of Wisconsin-Madison before joining Genus in 1995.

Β 

Separately, Ian Biggs, formerly Head of Global Product and Business Strategy, has stepped down from his role to pursue other opportunities outside Genus. His primary responsibilities will be assumed by Dr. Denny Funk.

Β 

Karim Bitar, Chief Executive, commented:

Β 

Β "I am delighted to announce the appointment of such a high calibre and experienced individual as Catherine to the role of Group HR Director. Catherine has been attracted and inspired by the Group's ambitious plans and is as enthusiastic as I am about the opportunities ahead. She will play a major role as she helps shape our talent management strategy."

Β 

"I would like thank Ian for the contribution he has made to Genus over the years and we wish him all the best for the future. Lastly, I am delighted that Denny has taken overall responsibility for R&D and I look forward to working with him closely as we ensure R&D plays a clear and consistent part in helping Genus meet evolving customer and market needs."

Β 

Β 

Β 

Β 

Β 

For further information please contact:

Β 

Genus plc Tel: 01256 345970

Karim Bitar, Chief Executive

John Worby, Finance Director

Β 

Buchanan Tel: 0207 466 5000

Charles Ryland, Suzanne Brocks, Catherine Breen

www.buchanan.uk.comΒ 

Β 

Β 

This announcement is available on the Genus website, www.genusplc.com

Β 

Β 

About Genus

Β 

Genus creates advances to animal breeding through biotechnology and sells added value products for livestock farming and food producers. Its non-genetically modified organism technology is applicable across all livestock species but is only commercialised by Genus in the bovine and porcine farming sectors.

Β 

Genus' worldwide sales are made in seventy countries under the trademarks "ABS" (dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals with superior genetics to those animals currently in production. Customers' animals produce offspring with greater production efficiency, milk and meat output and quality, and use these to supply the global dairy and meat supply chain.

Β 

The Group's competitive edge has been created from the ownership and control of proprietary lines of breeding animals, the biotechnology used to improve them and its global production and distribution network.

Β 

With headquarters in Basingstoke, England, Genus companies operate in thirty countries on six continents, with research laboratories located in Madison, Wisconsin, USA

Β 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCBJMRTMBJMBLT
Date   Source Headline
3rd Oct 20132:00 pmRNSAdditional Listing
2nd Oct 20135:00 pmRNSTotal Voting Rights
27th Sep 20136:19 pmRNSDirector/PDMR Shareholding
23rd Sep 20137:00 amRNSGenus to Acquire Génétiporc
3rd Sep 20133:04 pmRNSCorrection of Record Date
3rd Sep 20137:00 amRNSPreliminary Results
31st Jul 20133:00 pmRNSBlocklisting Interim Review
25th Jul 201310:14 amRNSCompany Secretary Appointment
18th Jul 20139:00 amRNSHolding(s) in Company
11th Jun 20135:07 pmRNSHolding(s) in Company
4th Jun 20139:10 amRNSHolding(s) in Company
31st May 20132:00 pmRNSTotal Voting Rights
23rd May 20138:22 amRNSDirector/PDMR Shareholding
21st May 20134:56 pmRNSHolding(s) in Company
30th Apr 20137:00 amRNSInterim Management Statement
8th Apr 20136:09 pmRNSHolding(s) in Company
8th Apr 201310:27 amRNSHolding(s) in Company
28th Mar 20134:13 pmRNSHolding(s) in Company
28th Mar 20133:51 pmRNSTotal Voting Rights
21st Mar 20132:00 pmRNSHolding(s) in Company
11th Mar 20134:07 pmRNSDirector/PDMR Shareholding
4th Mar 20132:00 pmRNSHolding(s) in Company
28th Feb 20132:30 pmRNSTotal Voting Rights
28th Feb 20132:00 pmRNSDirector/PDMR Shareholding
25th Feb 20134:21 pmRNSDirector/PDMR Shareholding
25th Feb 20137:00 amRNSInterim Results
25th Feb 20137:00 amRNSSecond New Joint Venture in China
4th Feb 201310:00 amRNSHolding(s) in Company
31st Jan 20132:00 pmRNSBlocklisting Interim Review
31st Jan 20132:00 pmRNSTotal Voting Rights
8th Jan 20132:00 pmRNSHolding(s) in Company
13th Dec 20127:00 amRNSDirectorate Change
7th Dec 201210:00 amRNSDirector/PDMR Shareholding
30th Nov 20122:00 pmRNSTotal Voting Rights
14th Nov 201210:00 amRNSHolding(s) in Company
8th Nov 20123:30 pmRNSAGM Statement
8th Nov 20127:00 amRNSAGM and Interim Management Statement
31st Oct 20122:03 pmRNSTotal Voting Rights
26th Oct 201210:00 amRNSHolding(s) in Company
17th Oct 201210:00 amRNSHolding(s) in Company
9th Oct 20122:00 pmRNSAnnual Report and details of AGM
28th Sep 20122:00 pmRNSTotal Voting Rights
27th Sep 201211:00 amRNSAdditional Listing
27th Sep 20128:00 amRNSHolding(s) in Company
26th Sep 20124:01 pmRNSDirector/PDMR Shareholding
4th Sep 20127:00 amRNSPreliminary Results
31st Aug 20122:00 pmRNSTotal Voting Rights
23rd Aug 20126:18 pmRNSHolding(s) in Company
20th Aug 20127:00 amRNSAppointment of Joint Broker
31st Jul 20122:00 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.